Info

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. The Company’s initial development efforts address products that treat gastrointestinal infections (GI) infections, and related diseases, where therapies have limitations, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance and bacterial resistance. Optimer has two late-stage, anti-infective product candidates: OPT-80 and Prulifloxacin. OPT-80, its principal product candidate, is an antibiotic in two Phase III registration trials for the treatment of Clostridium difficile-infections (CDI) also known as Clostridium difficile-associated disease (CDAD) the most common nosocomial diarrhea. Prulifloxacin is an antibiotic in two Phase III trials for the treatment of infectious diarrhea in travelers, a community-acquired infection, which can be caused by a range of bacteria.(Source: 10-K)